2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Related Products

PDF 1.4 MB

Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS00150
    Ace Mouse Pre-designed siRNA Set A
    		Inhibitor

    Ace Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ace gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ace Mouse Pre-designed siRNA Set A
    Ace Mouse Pre-designed siRNA Set A
  • HY-P10808
    RSRGVFF
    		Inhibitor
    RSRGVFF (FOXP3 inhibitor P60) is a mixed-type angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, boasting an IC50 value of 5.01 μM. RSRGVFF is capable of binding to both active and non-active sites of ACE and its substrate HHL complex, thus reducing the catalytic activity of ACE. RSRGVFF can be further utilized for research on lowering hypertension.
    RSRGVFF
  • HY-P3991
    Bradykinin potentiator C
    		Inhibitor
    Bradykinin potentiator C is a potent angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 7.1 μM for rabbit lung ACE. Bradykinin potentiator C is a postulated prototype of functional peptide.
    Bradykinin potentiator C
  • HY-126826
    Antibiotic K 4
    		Inhibitor
    Antibiotic K 4 is an inhibitor of angiotensin I converting enzyme (ACE) (Ki: 0.18 μM). Antibiotic K 4 inhibits pressor response to angiotensin I in rats.
    Antibiotic K 4
  • HY-13771R
    Ursodeoxycholic acid (Standard)
    		Inhibitor
    Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
    Ursodeoxycholic acid (Standard)
  • HY-P5913
    [Tyr6]-Angiotensin II
    [Tyr6]-Angiotensin II is a peptide fragment , and can bind to the angiotensin converting enzyme 2 .
    [Tyr6]-Angiotensin II
  • HY-14923
    Ilepatril
    		Inhibitor
    Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy.
    Ilepatril
  • HY-B0592A
    Trandolapril hydrochloride
    		Inhibitor
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
    Trandolapril hydrochloride
  • HY-114424
    H-Ile-Pro-Pro-OH
    		Inhibitor
    H-Ile-Pro-Pro-OH, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM. Antihypertensive tripeptides.
    H-Ile-Pro-Pro-OH
  • HY-143886
    AD011
    AD011 is a dual inhibitor of cACE/NEP. AD011 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD011 has the potential for providing the potent antihypertensive and cardioprotective benefits.
    AD011
  • HY-P990731
    Canvircept
    Canvircept is a recombinant fusion protein comprising an angiotensin-converting enzyme 2 (ACE2) fused to a human IgG1 Fc.
    Canvircept
  • HY-RS00151
    ACE Rat Pre-designed siRNA Set A
    		Inhibitor

    ACE Rat Pre-designed siRNA Set A contains three designed siRNAs for ACE gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    ACE Rat Pre-designed siRNA Set A
    ACE Rat Pre-designed siRNA Set A
  • HY-A0230
    Spirapril
    		Inhibitor
    Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure.
    Spirapril
  • HY-P2616
    Mca-YVADAP-Lys(Dnp)-OH
    		Chemical
    Mca-YVADAP-Lys(Dnp)-OH is a fluorogenic substrate for caspase-1 and angiotensin-converting enzyme 2 (ACE2).
    Mca-YVADAP-Lys(Dnp)-OH
  • HY-113681
    REV 5975
    		Inhibitor
    REV 5975 is a angiotensin converting enzyme (ACE) inhibitor. REV 5975 shows a partial reduction of the angiotensin I effect.
    REV 5975
  • HY-143888
    AD013
    AD013 is a dual inhibitor of cACE/NEP. AD013 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD013 has the potential for providing the potent antihypertensive and cardioprotective benefits.
    AD013
  • HY-127026A
    Quinaprilat hydrate
    		Inhibitor
    Quinaprilat hydrate is a non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrate specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrate acts as anti-hypertensive agent and vasodilator.
    Quinaprilat hydrate
  • HY-105266
    Zabicipril
    		Inhibitor
    Zabicipril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril can be used for the study of blood pressure and peripheral arterial insufficiency.
    Zabicipril
  • HY-P3976
    Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine
    		Inhibitor 99.78%
    Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is a blood pressure lowering peptide containing 4 amino acids. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine is an angiotensin-converting Enzyme (ACE) inhibitor. Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine can be used in research of high blood pressure.
    Lactalbumin B (50-53) Alpha [Lactorphin Alpha], bovine
  • HY-B0093AS
    Benazepril-d5 hydrochloride
    		Inhibitor
    Benazepril-d5 hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.
    Benazepril-d<sub>5</sub> hydrochloride
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity